期刊文献+

单器官转移的非小细胞肺癌化疗并同步胸部三维放疗的临床研究 被引量:1

Clinical value of concurrent chemotherapy and thoracic three dimensional conformal radiotherapy for single organ metastasis of non-small cell lung cancer
原文传递
导出
摘要 目的探讨单器官转移的非小细胞肺癌化疗并同步胸部三维放疗的疗效。方法将100例确诊单器官转移的非小细胞肺癌患者信封法随机分为同步放化疗组和化疗组,各50例,两组化疗方案均采用紫杉醇加顺铂,共化疗4个周期,紫杉醇135~150mg/m^2,第1天,顺铂25mg/m^2,第2-4天静滴。同步放化疗组在化疗第1天给予同期放疗60Gy/30次/6周。结果同步放化疗组患者的治疗疗效和生活质量方面的总控制率分别为90.0%和96.0%,均明显高于化疗组(70.0%和82.0%),组间差异均有统计学意义(P〈0.05)。同步放化疗组患者的无疾病进展生存期为5.6个月,与化疗组(3.2个月)相比差异有统计学意义(P〈0.05)。同步放化疗组患者的不良反应与化疗组相比差异无统计学意义(P〉0.05)。结论单器官转移的非小细胞肺癌化疗并同步胸部三维放疗能提高患者的临床疗效和生活质量,不良反应均可耐受。 Objective To investigate the efficacy and safety of concurrent chemotherapy and tho- racic three-dimensional conformal radiotherapy for single organ metastasis of non-small cell lung cancer (NSCLC). Methods A total of 100 patients who were diagnosed as single organ metastasis of NSCLC were envelope randomization method divided into concurrent chemoradiotherapy group (50 cases) and chemother- apy group (50 cases). All patients received paclitaxel and cisplatin chemotherapy 4 cycles, paclitaxel 135 - 150 mg/m^2 on day 1, cisplatin 25 mg/m^2 , on day 2 - 4. Patients in concurrent chemoradiotherapy group received radiotherapy with concurrent 60 Gy/30 times/6weeks on the first day of chemotherapy. Re- sults Total effective rate of curative effect and life of quality in concurrent chemoradiotherapy group (90. 0% and 96. 0% ) were higher than those of chemotherapy group (70.0% and 82.0% ), with signifi- cant differences ( P 〈 0. 05 ) ; Non-disease progression time of the concurrent chemoradiotherapy group were 5.6 months, significant higher than that of the control group (3.2 months) , and the differences were statis- tically significant between two groups ( P 〈 0. 05 ). The toxicity and adverse effects between two groups were no statistically significant ( P 〉 0. 05 ). Conclusion Concurrent chemotherapy and thoracic three-dimen- sional conformal radiotherapy could improve clinical efficacy and quality of life of single organ metastasis of NSCLC. Toxicity can be tolerated.
出处 《中国肿瘤临床与康复》 2015年第5期516-518,共3页 Chinese Journal of Clinical Oncology and Rehabilitation
基金 秦皇岛市科学技术研究与发展计划项目(No.201401A092)
关键词 非小细胞肺 同期化放疗 三维适形放疗 治疗结果 不良反应 Carcinomar, non-small cell lung Concurrent chemoradiotherapy Three-dimen-sional conformal radiotherapy Therapy outcome Toxicity
  • 相关文献

参考文献8

  • 1卢冰.现代放疗能否使选择性Ⅳ期非小细胞肺癌患者获益[J].肿瘤预防与治疗,2009,22(4):355-359. 被引量:3
  • 2李凤虎,卢冰,付和谊,韩蕾,李青松,栗惠芹.546例Ⅳ期非小细胞肺癌远处转移特点的放疗意义分析[J].中华放射肿瘤学杂志,2012,21(2):122-125. 被引量:18
  • 3Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 american society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer[J]. J Clin Oncol, 2011,29:3825-3831.
  • 4傅小龙.放疗在晚期非小细胞肺癌治疗中的地位[M].北京:人民卫生出版社,2013:82-86.
  • 5卢冰.从三维放射治疗技术进展思考Ⅳ期非小细胞肺癌的胸部放疗[J].实用肿瘤学杂志,2012,26(1):55-59. 被引量:5
  • 6Cheruvu P, Metcalfe SK, Metcalfe J, et al. Comparison of out- comes in patients with stage III versus limited stage IV nonsmall cell lung cancer[ J]. Radiat Oncol, 2011,6:80.
  • 7Simon AE, Juszczyk D, Smyth N, et al. Knowledge of lung cancer symptoms and risk factors in the UK:development of a measure and results from a population-based survey[ J]. Thorax, 2012, 67:426-432.
  • 8Gimux Leprieur E, Lavole A, Ruppert AM. et al. Factors associ- ated with long-term survival of patients with advanced non-small cell lung cancer[J]. Respimlogy, 2012, 17:134-142.

二级参考文献99

  • 1李雅莉,杨德昌.肺癌的诊断及其进展[J].国外医学(呼吸系统分册),2005,25(2):124-126. 被引量:13
  • 2高云,方健,刘叙仪,林宝和,安彤同,高非.305例非小细胞肺癌骨转移的诊断、治疗及预后分析[J].中国肺癌杂志,2006,9(4):357-361. 被引量:18
  • 3Joan H,Schiller.晚期非小细胞肺癌的化疗// Harver I. Pass,James B. Mitchell, David H. Johnson, et al,主编.Lung Cancer.冯玉麟,刘春涛译.北京:人民卫生出版社,2002:819-832.
  • 4王绿化,张红星,陈东福.肺癌//殷蔚伯,余子豪,徐国镇,等.主编.肿瘤放射治疗学.4版.北京:中国协和医科大学出版社,2008:578-611.
  • 5Harver I. Pass, James B. Mitchell, David H. Johnson, et al.Lung Cancer[M].北京:人民卫生出版社,2002:819-946.
  • 6Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent nonsmall- cell lung cancer[ J]. Lung Cancer, 2003, 39: 55-61.
  • 7Fossella FV, DeVote R, Ker RN, et al. Randomized phase III trial of doeetaxel versus vinorebine or ifosfamide in patients with advanced non- small cell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group[J]. J Clin Oneol, 2000, 18: 2354-2362.
  • 8Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy[ J]. J Clin Oncol, 2004, 22 : 1589 - 1597.
  • 9Loriot Y, Sofia J-C, Le Chevalier T, et al. Expanding role of chemotherapy in lung cancer[ J]. Annals of Ontology, 2006, 17 ( supple 10) : 101 - 107( ESMO).
  • 10Ciuleanu TE, Brodowicz T, Belani CP. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study[J]. Proc Am Soc Clin Oncol, 2008, 26: 20S.

共引文献23

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部